Clinical Trials Logo

Filter by:
NCT ID: NCT06420206 Recruiting - Lung Cancer Clinical Trials

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

Start date: May 14, 2024
Phase: N/A
Study type: Interventional

To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.

NCT ID: NCT06420167 Not yet recruiting - Clinical trials for Renal AL Amyloidosis

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

FLORAL
Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: - screened for the trial via an online platform - contacted by study personal to obtain electronic consent - enrolled in the trial if eligible and consented - contacted by study personal for further instructions and directions - sent dapagliflozin oral medication (supplied by the site pharmacy) - followed up regularly with the study team via telemedicine or other online avenues - monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months - continue treatment for 6 months

NCT ID: NCT06420141 Recruiting - Neuropathic Pain Clinical Trials

The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture

Start date: January 3, 2024
Phase:
Study type: Observational

This application addresses the Peer Reviewed Medical Research Program Investigator-Initiated Research Award FY21 W81XWH-22-CPMRP-IIRA area of Chronic Pain Management Research Program- The investigators will utilize subjects who have sustained ankle fractures and may develop chronic pain following bone union. No attempt will be made to affect the experimental outcome in the subjects. This study will adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of research.

NCT ID: NCT06420089 Not yet recruiting - Clinical trials for T Cell Non-Hodgkin Lymphoma

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

VIPER101
Start date: June 30, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.

NCT ID: NCT06420050 Not yet recruiting - Heavy Drinking Clinical Trials

Testing a Novel Instagram Intervention for Heavy Alcohol Use

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

This project aims to test the efficacy of an Instagram-based intervention for reducing heavy alcohol use. More specifically, the investigators will use a randomized controlled design to analyze differences in alcohol use and alcohol-related outcomes (e.g., alcohol-related consequences, etc.) as well as differences in the use of protective behavioral strategies and mindfulness practices. Participants (80 Prolific users who report binge drinking) will be randomly assigned to 1 of 3 conditions: intervention or control. Those who are randomized to the intervention condition will be invited to follow study Instagram pages, and those who are randomized to the control condition will be invited to complete the assessments only. The investigators hypothesize that there will be greater reductions in alcohol use, frequency, and consequences and greater frequency of use of mindfulness exercises and protective behavioral strategies among those in the intervention condition as compared to those in the control condition.

NCT ID: NCT06419985 Not yet recruiting - Clinical trials for Complex Regional Pain Syndromes

Ketamine HCl Prolonged Release Oral Tablets for CRPS

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments, and efficacy signals.

NCT ID: NCT06419959 Not yet recruiting - Clinical trials for Cardiovascular Diseases

NightWare and Cardiovascular Health in Veterans With PTSD

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about the effectiveness of a prescription wrist-wearable device called NightWare (NW) on improving sleep in Veterans with nightmares related to posttraumatic stress disorder (PTSD). The investigators also want to learn whether it improves cardiovascular health among this population.

NCT ID: NCT06419920 Not yet recruiting - Amputation Clinical Trials

Prosthetic Performance Enhancement Trial

PROSPER
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this research is to determine the feasibility of an uneven terrain walking program for lower limb prosthesis users. The training is designed to induce step-to-step variability during walking within a safe environment, with the aim of improving walking skill and confidence.

NCT ID: NCT06419803 Not yet recruiting - Pregnancy Related Clinical Trials

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

START2
Start date: May 27, 2024
Phase: N/A
Study type: Interventional

The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a Strict and permissive threshold. The Strict study arm target range will be 65-120 mg/dL, with time in range goal of 70%. The permissive study arm target range will be 65-140 mg/dL, with target time in range goal of 70%.

NCT ID: NCT06419777 Not yet recruiting - Pregnancy Related Clinical Trials

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

START 1
Start date: May 31, 2024
Phase: N/A
Study type: Interventional

The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the permissive threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).